Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H1 2017

  • ID: 4315554
  • Report
  • 35 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Globavir Biosciences Inc
  • HitGen LTD
  • NewLink Genetics Corp
  • Pfizer Inc
  • MORE
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H1 2017

Summary:

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report Tryptophan 2,3 Dioxygenase - Pipeline Review, H1 2017, outlays comprehensive information on the Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Tryptophan 2, 3-dioxygenase is an enzyme that plays a critical role in tryptophan metabolism by catalyzing the first and rate-limiting step of the kynurenine pathway. It has specificity towards tryptamine and derivatives including D- and L-tryptophan, 5-hydroxytryptophan and serotonin. The molecules developed by companies in Preclinical and Discovery stages are 8 and 3 respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Glioblastoma Multiforme (GBM), Melanoma, Bladder Cancer, Liver Cancer and Parkinson's Disease.

Furthermore, this report also reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)
  • The report reviews Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • F. Hoffmann-La Roche Ltd
  • Globavir Biosciences Inc
  • HitGen LTD
  • NewLink Genetics Corp
  • Pfizer Inc
  • MORE
  1. Introduction
  2. Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Overview
  3. Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Companies Involved in Therapeutics Development
  13. Ensemble Therapeutics Corp
  14. F. Hoffmann-La Roche Ltd
  15. Globavir Biosciences Inc
  16. HitGen LTD
  17. Netherlands Translational Research Center BV
  18. NewLink Genetics Corp
  19. Pfizer Inc
  20. Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Drug Profiles
  21. GBV-1012 - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. GBV-1073 - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. RG-70099 - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. Small Molecule to Inhibit TDO-2 for Oncology - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. Small Molecules to Inhibit TDO for Oncology - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. Small Molecules to Inhibit TDO for Oncology - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. Small Molecules to Inhibit TDO for Oncology - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. Small Molecules to Inhibit TDO for Parkinson's Disease - Drug Profile
  58. Product Description
  59. Mechanism Of Action
  60. R&D Progress
  61. Small Molecules to Inhibit TDO2 for Oncology - Drug Profile
  62. Product Description
  63. Mechanism Of Action
  64. R&D Progress
  65. Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Dormant Products
  66. Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Product Development Milestones
  67. Featured News & Press Releases
  68. Feb 10, 2015: IOmet Pharma demonstrates superior in vivo PK/PD properties in pre-clinical IDO, TDO and Dual IDO/TDO cancer immunotherapy programs
  69. Feb 06, 2015: IOmet Pharma to present data on pre-clinical cancer immunotherapy programs at Keystone Tumor Immunology Symposium
  70. Appendix
  71. Methodology
  72. Coverage
  73. Secondary Research
  74. Primary Research
  75. Expert Panel Validation
  76. Contact Us
  77. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Stage and Route of Administration, H1
  8. Number of Products by Stage and Molecule Type, H1
  9. Pipeline by Ensemble Therapeutics Corp, H1
  10. Pipeline by F. Hoffmann-La Roche Ltd, H1
  11. Pipeline by Globavir Biosciences Inc, H1
  12. Pipeline by HitGen LTD, H1
  13. Pipeline by Netherlands Translational Research Center BV, H1
  14. Pipeline by NewLink Genetics Corp, H1
  15. Pipeline by Pfizer Inc, H1
  16. Dormant Projects, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Ensemble Therapeutics Corp
  • F. Hoffmann-La Roche Ltd
  • Globavir Biosciences Inc
  • HitGen LTD
  • Netherlands Translational Research Center BV
  • NewLink Genetics Corp
  • Pfizer Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll